Revista Peruana de Medicina de Experimental y Salud Publica最新文献_第5页

Diagnostic performance of a point-of-care molecular system for the detection of SARS-CoV-2 in Peru. 秘鲁用于检测 SARS-CoV-2 的护理点分子系统的诊断性能。

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13046

Zully M Puyén, Roger Araujo-Castillo, Jorge Giraldo, Karina Gutierrez, Nancy Rojas-Serrano

{"title":"Diagnostic performance of a point-of-care molecular system for the detection of SARS-CoV-2 in Peru.","authors":"Zully M Puyén, Roger Araujo-Castillo, Jorge Giraldo, Karina Gutierrez, Nancy Rojas-Serrano","doi":"10.17843/rpmesp.2024.411.13046","DOIUrl":"10.17843/rpmesp.2024.411.13046","url":null,"abstract":"The present study assessed the diagnostic performance of the Xpert®Xpress SARS-CoV-2 test in comparison with the Charité protocol real-time RT PCR for the detection of SARS-CoV-2 in Peruvian patients. This was a diagnostic test study that included 100 nasal and pharyngeal swab samples. We obtained an overall concordance of 98.70% (95%CI: 92.98-99.97), with a kappa coefficient of 0.97 (95%CI: 0.86-1.00) and sensitivity and relative specificity rates of 100% and 96.15%, respectively. Additionally, the percentage of the area under the ROC curve was 98.08% in both cases, and an analytical specificity rate of 100% was obtained for the different respiratory viruses evaluated. In conclusion, the Xpert®Xpress SARS-CoV-2 test, by using nasal and pharyngeal swab samples, was highly sensitive and specific, and the kappa coefficient showed an excellent correlation when compared to the reference test. Motivation for the study. To describe and evaluate a closed molecular platform, easy to use and of importance in Peru for the management of diseases of public health priority, now implemented for the detection of SARS-CoV-2. Main findings. Highly sensitive and specific molecular test, with excellent correlation compared to the reference test for detecting SARS-CoV-2. Implications. Can be used in point-of-care laboratories for rapid molecular detection of different infectious agents, including SARS-CoV-2. Little expertise and minimal infrastructure are required to implement it.","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"76-82"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coexistence of adult mosquitoes (Diptera: Culicidae) inside dwellings in a rural community during a dengue outbreak in Sullana, Piura, 2023. 2023 年皮乌拉苏拉纳爆发登革热疫情期间农村社区住宅内的成蚊（双翅目：Culicidae）共存情况。

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13416

Archi Alejandro Ruiz-Polo, Carlos Martín Núñez-Rodríguez, Cindy Yuriko Saavedra-Ríos, Lya Emilia Niño-Mendoza, Rosa Elena Santillan-Valdivia

引用次数: 0

Cost of controlling the dengue vector Aedes aegypti in the Peruvian amazon. 秘鲁亚马孙地区控制登革热病媒埃及伊蚊的成本。

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.12905

Salomon Durand, Arles Paredes, Carlos Pacheco, Ray Fernandez, Jose Herrera, César Cabezas

{"title":"Cost of controlling the dengue vector Aedes aegypti in the Peruvian amazon.","authors":"Salomon Durand, Arles Paredes, Carlos Pacheco, Ray Fernandez, Jose Herrera, César Cabezas","doi":"10.17843/rpmesp.2024.411.12905","DOIUrl":"10.17843/rpmesp.2024.411.12905","url":null,"abstract":"Objective.: Motivation for the study. Dengue prevention and control is based on the control of its vector. This study was conducted because of the need to know the costs associated with Aedes aegypti control in a region that carries out planned vector control activities. Main findings. The costs incurred in dengue vector control in the Loreto region in 2017 and 2018 amounted to PEN 4,066,380.25 and PEN 3,807,858.73, respectively. Implications. Knowing the cost of vector control activities will allow us to better plan these activities and have a basis for cost-effectiveness studies with other methods of prevention and control of dengue. To estimate the costs incurred in the control of Aedes aegypti in the Loreto region, during the years 2017 and 2018.Materials and methods.: We conducted a partial retrospective economic evaluation of the costs of Aedes aegypti control of the Regional Health Directorate Loreto, during the implementation of the Regional Plan for Surveillance and Control of Aedes aegypti. Documentation such as plans, intervention reports and payment slips were reviewed, and interviews were conducted with professional personnel involved in vector control, on the costs of control interventions.Results.: We found that the costs incurred in dengue vector control in the Loreto Region in the two years were: PEN 3,807,858 and PEN 4,066,380 during 2017 and 2018, respectively (USD 1,175,264 and USD 1,1210,232 at the 2017 and 2018 exchange rate). However, the effect of control activities is short-lived.Conclusions.: The high cost involved in vector control with the methods currently used and the short duration of its effect make it unsustainable. Studies should be conducted in order to find other more efficient methods for dengue control.","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"46-53"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast cancer in northern Peru: molecular subtypes and HER2 low. 秘鲁北部的乳腺癌：分子亚型和 HER2 低值。

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13424

Katherine Gómez-Rázuri, Milagros Abad-Licham, Juan Astigueta, Joan Moreno

{"title":"Breast cancer in northern Peru: molecular subtypes and HER2 low.","authors":"Katherine Gómez-Rázuri, Milagros Abad-Licham, Juan Astigueta, Joan Moreno","doi":"10.17843/rpmesp.2024.411.13424","DOIUrl":"10.17843/rpmesp.2024.411.13424","url":null,"abstract":"This study aimed to understand the immunohistochemical profile of breast cancer and to identify the HER2 low subgroup in the northern macro-region of Peru. A cross-sectional study was conducted in 1176 patients from the Regional Institute of Neoplastic Diseases Northern Peru, from January 2016 to December 2023. We analyzed the data (age, histological type, grade and complementary results), with frequencies and percentages. The profile corresponded to: luminal B (45.6%); luminal A (24.7%); triple negative (18.2%); and HER2 positive non luminal (11.5%). In addition, 215 patients presented HER2 low (25.1% of those previously considered negative). This study provides evidence that the subtyping of breast cancer has changed, being luminal B the most frequent. It is essential to involve health policies to acquire targeted therapies considering HER2 low patients. Motivation for the study. Molecular classification of breast cancer allows the use of targeted treatments. Information on this profile in the northern macroregion of Peru is unknown. In addition, new therapies have appeared for a subgroup of patients. Main findings. In this study, the most frequent molecular subtypes were: luminal B, luminal A, triple negative and non-luminal HER2. Also, 18.3% of patients had low HER2 expression. Implications. Health policies should be aligned with scientific advances, to guarantee targeted therapies and to update the information in health manuals or protocols.","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"62-68"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

El tamaño del empaque de las galletas ultraprocesadas evita que lleven octógonos a pesar de tener alto contenido de azúcar y grasas saturadas 超加工饼干的包装尺寸防止了它们有八角形，尽管糖和饱和脂肪含量很高

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2023-09-28 DOI: 10.17843/rpmesp.2023.403.13119

Mayra Meza-Hernández, Kiomi Yabiku-Soto, Lorena Saavedra-Garcia, Francisco Diez-Canseco

引用次数: 0

Enfermedades endocrinas asociadas a vacunación por la COVID-19: reporte de casos 与COVID-19疫苗接种相关的内分泌疾病:病例报告

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2023-09-28 DOI: 10.17843/rpmesp.2023.403.12572

Alberto A. Teruya-Gibu, Percy Ortiz-Guerra, Abad A. Arzapalo-Poma

引用次数: 0

Prioridades nacionales de investigación en salud bucal, Perú 2022-2026: proceso, experiencias y perspectivas 秘鲁2022-2026年国家口腔健康研究优先事项:进程、经验和前景

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2023-09-28 DOI: 10.17843/rpmesp.2023.403.12082

Adriana Echevarria-Goche, Gilmer Solis-Sánchez, Lesly V. Tuesta-Orbe, Christian Andamayo-Flores, Margot Vidal-Anzardo

{"title":"Prioridades nacionales de investigación en salud bucal, Perú 2022-2026: proceso, experiencias y perspectivas","authors":"Adriana Echevarria-Goche, Gilmer Solis-Sánchez, Lesly V. Tuesta-Orbe, Christian Andamayo-Flores, Margot Vidal-Anzardo","doi":"10.17843/rpmesp.2023.403.12082","DOIUrl":"https://doi.org/10.17843/rpmesp.2023.403.12082","url":null,"abstract":"El Instituto Nacional de Salud, ha llevado a cabo por primera vez el proceso de identificación de PrioridadesNacionales de Investigación en Salud Bucal a cargo de la Subdirección de Investigación y Laboratorios de Enfermedades No Transmisibles del Centro Nacional de Salud Pública con la asesoría técnica de la Dirección de Investigación e Innovación en Salud y en coordinación con la Dirección Ejecutiva de Salud Bucal de la Dirección General de Intervenciones Estratégicas en Salud Pública del Ministerio de Salud mediante metodología participativa de tres actores claves: investigadores/especialistas, expertos y decisores. El objetivo de este artículo es describir el proceso seguido para la identificación de estas prioridades, el cual comprendió cinco fases: i) identificación de objetivos estratégicos del MINSA, ii) identificación de necesidades de investigación en salud bucal, iii) revisión por expertos y valoración de las necesidades según criterios, iv) priorización (valoración de la lista de prioridades según calificación) y v) presentación de las prioridades. Como resultado se obtuvieron las 12 prioridades que posteriormente fueron aprobadas por Resolución Ministerial N.° 262-2022/MINSA, con un periodo de vigencia2022–2026. Además, se brindaron recomendaciones para futuros procesos.","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"98 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135470102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Neutralización del coronavirus SARS-CoV-2 por suero hiperinmune de llama (Lama glama) en cultivo de células Vero 超免疫美洲驼（Lama glama）血清在 Vero 细胞培养中对 SARS-CoV-2 冠状病毒的中和作用

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2023-09-28 DOI: 10.17843/rpmesp.2023.403.12509

Verónica Yaniro, Silvia Capristano, Henri Bailon, Juan Lévano, Marco Galarza, David García, Omar Cáceres, Carlos Padilla, Harrison Montejo, Paquita García, Mary Celis, Silvia Seraylan, Yessica Garayar, Miryam Palomino

{"title":"Neutralización del coronavirus SARS-CoV-2 por suero hiperinmune de llama (Lama glama) en cultivo de células Vero","authors":"Verónica Yaniro, Silvia Capristano, Henri Bailon, Juan Lévano, Marco Galarza, David García, Omar Cáceres, Carlos Padilla, Harrison Montejo, Paquita García, Mary Celis, Silvia Seraylan, Yessica Garayar, Miryam Palomino","doi":"10.17843/rpmesp.2023.403.12509","DOIUrl":"https://doi.org/10.17843/rpmesp.2023.403.12509","url":null,"abstract":"Objetivo. Evaluar la respuesta inmune de una llama (Lama glama) a la inmunización con el virus SARS-CoV-2 y la capacidad del suero inmune para neutralizar la infección por el virus en cultivo de células. Materiales y Métodos. Inmunizamos una llama con el virus SARS-CoV-2 inactivado y analizamos muestras de suero con un ensayo ELISA y Western Blot específico para SARS-CoV-2; además analizamos la neutralización viral en cultivo celular por la Prueba de Neutralización por Reducción de Placas (PRNT). Resultados. Se observó un aumento en la serorreactividad para la llama inmunizada desde la semana 4 en adelante, revelando la seroconversión inducida por la inmunización; con los títulos de anticuerpos más altos en el octavo refuerzo de inmunización. El análisis de Western Blot confirmó los resultados positivos de ELISA, y los anticuerpos del suero inmune reconocieron varias proteínas virales. El ensayo estándar de oro de neutralización (PRNT) mostró una neutralización viral visible, concordante con los resultados de ELISA y Western Blot. Conclusión. Por lo tanto, nuestros hallazgos sugieren este suero hiperinmune de llama como una posible fuente de anticuerpos terapéuticos contra las infecciones por el virus SARS-CoV-2 para evaluar en estudios posteriores.","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135470109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Capacidad antioxidante in vitro del Corryocactus brevistylus (sanky) y su efecto en la morfología del páncreas de ratas diabéticas inducidas con aloxano 四氧嘧啶对四氧嘧啶诱导糖尿病大鼠胰腺形态的体外抗氧化能力及其影响

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2023-09-28 DOI: 10.17843/rpmesp.2023.403.12481

Liz Delia Arostegui-Faustino, Oscar Gustavo Huamán-Gutiérrez

{"title":"Capacidad antioxidante in vitro del Corryocactus brevistylus (sanky) y su efecto en la morfología del páncreas de ratas diabéticas inducidas con aloxano","authors":"Liz Delia Arostegui-Faustino, Oscar Gustavo Huamán-Gutiérrez","doi":"10.17843/rpmesp.2023.403.12481","DOIUrl":"https://doi.org/10.17843/rpmesp.2023.403.12481","url":null,"abstract":"Objetivo. Determinar la capacidad antioxidante in vitro del Corryocactus brevistylus y su efecto sobre la glicemia y páncreas de ratas diabéticas inducidas con aloxano. Materiales y métodos. Se evaluó la capacidad antioxidante del extracto hidroetanólico de sanky (EHES) mediante la capacidad de reducir el 2,2-difenil-1-picrilhidracilo (DPPH) y la capacidad de reducir el ion férrico (FRAP). Se utilizaron 30 ratas adultas inducidas a diabetes con dos dosis de aloxano (80mg/kg), formándose cinco grupos (n=6), recibiendo lostratamientos vía orogástrica durante ocho días, el grupo I (agua), II (metformina 14mg/kg), grupos IIIIV-V zumo de sanky a 1,0; 4,0 y 16 mL/kg, respectivamente. La glicemia fue evaluada por el método rápido (glucómetro) (primer y octavo día). Terminado el tratamiento los animales fueron sacrificados y se les extrajo el páncreas, para su estudio histopatológico. Resultados. La capacidad antioxidante delEHES mediante el DPPH, mostró un IC50 de 0,77 mg/mL, y por el método FRAP se observó el TEACFRAP de 22,31μg/mg. La glicemia disminuyó en el octavo día de tratamiento, respecto al primer día; también se observó disminución de la glicemia en los grupos III-V, respecto al grupo I. A nivel histológico los grupos I-II presentaron atrofia severa y necrosis moderada de los islotes de Langerhans; los grupos IV-V presentaron hipertrofia y necrosis leve multifocal a nivel del islote. Conclusiones. El extracto de sanky presenta capacidad antioxidante in vitro y el zumo ejerce un efecto hipoglicemiante y protector en páncreas.","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135470101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

El control del tabaco en América Latina: logros, pendientes y nuevos desafíos 拉丁美洲烟草控制:成就、未决问题和新挑战

Revista Peruana de Medicina de Experimental y Salud Publica Pub Date : 2023-09-27 DOI: 10.17843/rpmesp.2023.403.13284

Andrea Alcaraz, Andrés Pichon-Riviere

引用次数: 0